143 related articles for article (PubMed ID: 24900280)
21. Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344.
Brodmerkel CM; Huber R; Covington M; Diamond S; Hall L; Collins R; Leffet L; Gallagher K; Feldman P; Collier P; Stow M; Gu X; Baribaud F; Shin N; Thomas B; Burn T; Hollis G; Yeleswaram S; Solomon K; Friedman S; Wang A; Xue CB; Newton RC; Scherle P; Vaddi K
J Immunol; 2005 Oct; 175(8):5370-8. PubMed ID: 16210643
[TBL] [Abstract][Full Text] [Related]
22. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor.
Sasaki S; Cho N; Nara Y; Harada M; Endo S; Suzuki N; Furuya S; Fujino M
J Med Chem; 2003 Jan; 46(1):113-24. PubMed ID: 12502365
[TBL] [Abstract][Full Text] [Related]
23. Novel, orally bioavailable gamma-aminoamide CC chemokine receptor 2 (CCR2) antagonists.
Pasternak A; Marino D; Vicario PP; Ayala JM; Cascierri MA; Parsons W; Mills SG; Maccoss M; Yang L
J Med Chem; 2006 Aug; 49(16):4801-4. PubMed ID: 16884289
[TBL] [Abstract][Full Text] [Related]
24. Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases Inhibitors.
Qin D; Lin X; Liu Z; Chen Y; Zhang Z; Wu C; Liu L; Pan Y; Laquerre S; Emery J; Fergusson J; Roland K; Keenan R; Oliff A; Kumar S; Cheung M; Su DS
ACS Med Chem Lett; 2021 Jun; 12(6):1005-1010. PubMed ID: 34141085
[TBL] [Abstract][Full Text] [Related]
25. When structure-affinity relationships meet structure-kinetics relationships: 3-((Inden-1-yl)amino)-1-isopropyl-cyclopentane-1-carboxamides as CCR2 antagonists.
Vilums M; Zweemer AJ; Barmare F; van der Gracht AM; Bleeker DC; Yu Z; de Vries H; Gross R; Clemens J; Krenitsky P; Brussee J; Stamos D; Saunders J; Heitman LH; IJzerman AP
Eur J Med Chem; 2015 Mar; 93():121-34. PubMed ID: 25666912
[TBL] [Abstract][Full Text] [Related]
26. A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists.
Subasinghe NL; Lanter J; Markotan T; Opas E; McKenney S; Crysler C; Hou C; O'Neill J; Johnson D; Sui Z
Bioorg Med Chem Lett; 2013 Feb; 23(4):1063-9. PubMed ID: 23294701
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological evaluation of phenyl piperidine derivatives as CCR2 antagonists.
Xia M; Hou C; Pollack S; Brackley J; DeMong D; Pan M; Singer M; Matheis M; Olini G; Cavender D; Wachter M
Bioorg Med Chem Lett; 2007 Nov; 17(21):5964-8. PubMed ID: 17869105
[TBL] [Abstract][Full Text] [Related]
28. Discovery and synthesis of 6,7,8,9-tetrahydro-5H-pyrido[4,3-c]azepin-5-one-based novel chemotype CCR2 antagonists via scaffold hopping strategy.
Qin LH; Wang ZL; Xie X; Long YQ
Bioorg Med Chem; 2018 Jul; 26(12):3559-3572. PubMed ID: 29805075
[TBL] [Abstract][Full Text] [Related]
29. Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5.
Hall SE; Mao A; Nicolaidou V; Finelli M; Wise EL; Nedjai B; Kanjanapangka J; Harirchian P; Chen D; Selchau V; Ribeiro S; Schyler S; Pease JE; Horuk R; Vaidehi N
Mol Pharmacol; 2009 Jun; 75(6):1325-36. PubMed ID: 19297521
[TBL] [Abstract][Full Text] [Related]
30. The discovery of potent, orally bioavailable pyrazolo and triazolopyrimidine CXCR2 receptor antagonists.
Porter DW; Bradley M; Brown Z; Canova R; Charlton S; Cox B; Hunt P; Kolarik D; Lewis S; O'Connor D; Reilly J; Spanka C; Tedaldi L; Watson SJ; Wermuth R; Press NJ
Bioorg Med Chem Lett; 2014 Jan; 24(1):72-6. PubMed ID: 24332493
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.
Yang H; Lin XF; Padilla F; Gabriel SD; Heilek G; Ji C; Sankuratri S; deRosier A; Berry P; Rotstein DM
Bioorg Med Chem Lett; 2009 Jan; 19(1):209-13. PubMed ID: 19014885
[TBL] [Abstract][Full Text] [Related]
32. Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672.
Yang MG; Xiao Z; Cherney RJ; Tebben AJ; Batt DG; Brown GD; Chen J; Cvijic ME; Dabros M; Duncia JV; Galella M; Gardner DS; Khandelwal P; Ko SS; Malley MF; Mo R; Pang J; Rose AV; Santella JB; Shi H; Srivastava A; Traeger SC; Wang B; Xu S; Zhao R; Barrish JC; Mandlekar S; Zhao Q; Carter PH
ACS Med Chem Lett; 2019 Mar; 10(3):300-305. PubMed ID: 30891130
[TBL] [Abstract][Full Text] [Related]
33. Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.
Dow RL; Li JC; Pence MP; Gibbs EM; LaPerle JL; Litchfield J; Piotrowski DW; Munchhof MJ; Manion TB; Zavadoski WJ; Walker GS; McPherson RK; Tapley S; Sugarman E; Guzman-Perez A; DaSilva-Jardine P
ACS Med Chem Lett; 2011 May; 2(5):407-12. PubMed ID: 24900321
[TBL] [Abstract][Full Text] [Related]
34. Discovery and SAR of 5-aminooctahydrocyclopentapyrrole-3a-carboxamides as potent CCR2 antagonists.
Cai C; McComsey DF; Hou C; O'Neill JC; Opas E; McKenney S; Johnson D; Sui Z
Bioorg Med Chem Lett; 2014 Feb; 24(4):1239-42. PubMed ID: 23916257
[TBL] [Abstract][Full Text] [Related]
35. Structural refinement and prediction of potential CCR2 antagonists through validated multi-QSAR modeling studies.
Amin SA; Adhikari N; Baidya SK; Gayen S; Jha T
J Biomol Struct Dyn; 2019 Jan; 37(1):75-94. PubMed ID: 29251559
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, structure-activity relationship and in vivo antiinflammatory efficacy of substituted dipiperidines as CCR2 antagonists.
Xia M; Hou C; DeMong DE; Pollack SR; Pan M; Brackley JA; Jain N; Gerchak C; Singer M; Malaviya R; Matheis M; Olini G; Cavender D; Wachter M
J Med Chem; 2007 Nov; 50(23):5561-3. PubMed ID: 17929797
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological profile of JNJ-27141491 [(S)-3-[3,4-difluorophenyl)-propyl]-5-isoxazol-5-yl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxyl acid methyl ester], as a noncompetitive and orally active antagonist of the human chemokine receptor CCR2.
Buntinx M; Hermans B; Goossens J; Moechars D; Gilissen RA; Doyon J; Boeckx S; Coesemans E; Van Lommen G; Van Wauwe JP
J Pharmacol Exp Ther; 2008 Oct; 327(1):1-9. PubMed ID: 18599682
[TBL] [Abstract][Full Text] [Related]
38. Progress in the discovery of CC chemokine receptor 2 antagonists, 2009 - 2012.
Carter PH
Expert Opin Ther Pat; 2013 May; 23(5):549-68. PubMed ID: 23428142
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and evaluation of cis-3,4-disubstituted piperidines as potent CC chemokine receptor 2 (CCR2) antagonists.
Cherney RJ; Nelson DJ; Lo YC; Yang G; Scherle PA; Jezak H; Solomon KA; Carter PH; Decicco CP
Bioorg Med Chem Lett; 2008 Sep; 18(18):5063-5. PubMed ID: 18722120
[TBL] [Abstract][Full Text] [Related]
40. Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.
Liverton NJ; Bednar RA; Bednar B; Butcher JW; Claiborne CF; Claremon DA; Cunningham M; DiLella AG; Gaul SL; Libby BE; Lyle EA; Lynch JJ; McCauley JA; Mosser SD; Nguyen KT; Stump GL; Sun H; Wang H; Yergey J; Koblan KS
J Med Chem; 2007 Feb; 50(4):807-19. PubMed ID: 17249648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
